New Chiral Method Measures Bicalutamide Enantiomers in Prostate Cancer Treatment
Click here to read this scientific poster descripting how Inotiv validated a new method for measuring the effectiveness of bicalutamide, a treatment for prostate cancer. Bicalutamide is a mix of two mirror-image molecules, but only one is active against cancer. This method separates and analyzes both forms in human blood plasma and prostate tissue.
Key Points:
- Analyzes both active and inactive forms of bicalutamide.
- Works for human blood plasma and prostate tissue samples.
- Provides a range of detection for both sample types.
- Uses protein precipitation and LC-MS/MS technology.
Read how this new method offers a more precise way to understand how well bicalutamide is working and could potentially improve treatment outcomes.
